ERBB2 and breast cancer: Recently, Zagouri et al. conducted a meta-analysis on intrathecal trastuzumab in patients with LM from HER2-positive BC, reporting a median PFS and OS of 5.2 and 13.2 months, respectively, as well as a CSF clearance in 56% of patients and a radiological improvement or stabilization in nearly 71% [160].